Cabometyx (cabozantinib) — Highmark

advanced renal cell carcinoma (RCC)

Initial criteria

age ≥ 18 years
diagnosis of advanced RCC (ICD-10: C64)
OR diagnosis of advanced RCC and using Cabometyx as a first-line treatment in combination with nivolumab